Recent Advances in Anticancer Activity of Gold(I) Complexes

Area of Science:

• Organometallic Chemistry
• Medicinal Chemistry
• Oncology

Background:

• Cisplatin's success drives research into new organometallic complexes for cancer therapy.
• Gold complexes, particularly those inhibiting thioredoxin reductase (TrxR), are gaining interest as anticancer agents.
• Auranofin repurposing highlights gold's potential in oncology.

Purpose of the Study:

• To compile and categorize major ligand modifications for gold(I) complexes used in anticancer research.
• To evaluate the in vitro anticancer activity of synthesized gold complexes.
• To establish structure-activity relationships (SAR) among different ligand classes.

Main Methods:

• Compilation and categorization of reported gold(I) complexes based on ligand type (sulfur, nitrogen, carbon, N-heterocyclic carbene).
• In vitro evaluation of synthesized gold complexes against various human cancer cell lines.
• Comparative analysis of cytotoxicity data to identify SAR.

Main Results:

• Gold(I) complexes with phosphine-carbon donor and bis-N-heterocyclic carbene (NHC) ligands demonstrated potent anticancer activity.
• Complex 68 (bis-NHC ligand) showed high potency against HL-60 leukemia cells (GI50 = 0.017 μM).
• Complex 49 (carbon-donor ligand) exhibited significant activity against A549 lung cancer cells (IC50 = 0.02 μM).

Conclusions:

• Rational ligand engineering is critical for enhancing the anticancer efficacy of gold(I) complexes.
• Gold(I) complexes represent a promising class of anticancer agents with potential for targeted drug delivery and multi-mechanistic therapies.
• The study provides a framework for developing next-generation gold-based therapeutics by identifying potent ligand scaffolds.